Ipsen to acquire Memo Therapeutics AG for over 700 million EUR
UNVERIFIED·Primary source · Financial Post
Ipsen entered a definitive agreement to acquire Memo Therapeutics AG.
The acquisition focuses on 'potravitug', a Phase II clinical-stage antibody for BK polyomavirus.
Total potential consideration exceeds 700 million EUR, with 200 million EUR paid at closing.
Key Facts
01
01 — What / Thesis
Ipsen to acquire Memo Therapeutics AG for over 700 million EUR
02
02 — Who / Subject
Ipsen, Memo Therapeutics AG
03
03 — Where / Locus
France, Switzerland
04
04 — When / Temporality
July 1, 2026
AI Verification Note
This article is generated by cross-referencing multiple sources and official announcements. Parts relying solely on testimony or reporting are reflected in the confidence score; content and assessment are updated as new information is confirmed.
